MICROPORT CARDIOFLOW
Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation MicroPort CardioFlow is dedicated to providing advanced minimally invasive therapies for structural heart diseases with its best-in-class capacities in R&D, manufacturing, marketing, and technical consulting services. We believe in “Focus, Innovation, and Globalization”, and in accordance, we place the utmost impor... tance on saving and improving quality of life for patients. Consequently, we constantly strive to bring the most innovative valvular disease treatment solutions to patients while also operating on a global vision to provide all patients and physicians with world-leading products that are superior, reliable, yet affordable.
MICROPORT CARDIOFLOW
Industry:
Health Care Manufacturing Medical Therapeutics
Founded:
2015-01-01
Status:
Active
Contact:
+ (86) (21) 38954600
Total Funding:
130 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Global Site Tag Euro US Privacy User Signal Mechanism Google Analytics 4 Pound Sterling
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Investors List
Hillhouse Capital Group
Hillhouse Capital Group investment in Private Equity Round - MicroPort CardioFlow
Gamnat
Gamnat investment in Private Equity Round - MicroPort CardioFlow
CPE
CPE investment in Private Equity Round - MicroPort CardioFlow
Lake Bleu Capital
Lake Bleu Capital investment in Private Equity Round - MicroPort CardioFlow
3H Health Investment
3H Health Investment investment in Private Equity Round - MicroPort CardioFlow
China Reform Fund Management
China Reform Fund Management investment in Private Equity Round - MicroPort CardioFlow
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-03-31 | 4C Medical Technologies | MicroPort CardioFlow investment in Series C - 4C Medical Technologies | 35.4 M USD |
More informations about "MicroPort CardioFlow"
Home - CardioFlow Medtech
CardioFlow Medtech Announces Annual Results for 2021. Shanghai, China, 29 March 2022 - MicroPort CardioFlow today announced the annual results of the Company and its subsidiaries for the 12 months ended December 31, 2021. In …See details»
MicroPort CardioFlow - Crunchbase Investor Profile
Shanghai MicroPort CardioFlow Medtech Co., Ltd. (MicroPort CardioFlow), founded 2015 in the Shanghai Zhangjiang Hi-Tech Park, is a subsidiary of MicroPort Scientific Corporation MicroPort CardioFlow is dedicated to …See details»
MicroPort CardioFlow Medtech Corporation 微创心通医疗科技有 …
“CRO” contract research organization, a company that provides support to the pharmaceutical, biotechnology, and medical device industries in the form of research services ... MICROPORT …See details»
MicroPort CardioFlow Medtech Corporation 2021 Annual Results …
News - CardioFlow Medtech
In the future, MicroPort CardioFlow will make greater breakthrough in market share and product innovation and provide global patients with trustworthy and universal access to state-of-the-art …See details»
MicroPort CardioFlow Medtech Corporation
Agenda 02 Appendices 19-25 Financial Review 05-08 Product Pipeline Update 09-14 Total Solutions Promotion Business Highlights 04 15-18 MicroPort CardioFlow Medtech CorporationSee details»
CardioFlow Medtech 2022 Interim Results | News | MicroPort
Aug 30, 2022 Founded in Shanghai in 2015, MicroPort CardioFlow Medtech Corporation (“CardioFlow Medtech”, stock code: 02160.HK), a subsidiary of MicroPort Scientific …See details»
News - CardioFlow Medtech
Aug 31, 2021 Shanghai, China — MicroPort CardioFlow Medtech Corporation (MicroPort CardioFlow), announced on August 29, 2021 the interim results of the Company and its …See details»
Jeff Lindstrom - President / Chief Executive Officer / …
President / Chief Executive Officer / Board Member (2023–Present) Advanced at organization with primary focus on designing and implementing strategic plans for global market expansion in ...See details»
VitaFlow Valve System Receives NMPA Approval | News - MicroPort
Jul 14, 2019 Shanghai, China - On July 12th, Shanghai MicroPort CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow"), which is a subsidiary of Shanghai MicroPort Medical (Group) Co., …See details»
2020 Annual Results Presentation - CardioFlow Medtech
MicroPort CardioFlow at a glance We are a medical device company in China focusing on research, development and commercialization of innovative transcatheter and surgical …See details»
MicroPort® CardioFlow Completes First Clinical Application of …
Jan 15, 2024 Previously, MicroPort® CardioFlow has completed several implantations of TMVR system under compassionate use. The immediate surgical outcomes, as well as follow-up …See details»
News - CardioFlow Medtech
According to Mr. Chen Guoming, Executive Director and President of MicroPort CardioFlow, “Thanks to the support of controlling shareholders of MicroPort ® and all investors from …See details»
CardioFlow's VitaFlow Liberty™ Granted EU CE-MDR Mark, …
MicroPort® CardioFlow Medtech Corporation (CardioFlow) (Stock Code: 02160.HK) recently announced that its self-developed second-generation transcatheter aortic valve implantation …See details»
Financial Reports | CARDIOFLOW
2024 Interim Report Report. 2023 Annual ReportSee details»
MicroPort® CardioFlow Receives Approval for VitaFlow Liberty® …
Shanghai, China, 9 May 2024 — MicroPort ® CardioFlow has obtained CE certification for its second-generation transcatheter aortic valve implantation (TAVI) product, VitaFlow Liberty ® …See details»
News - CardioFlow Medtech
Nov 5, 2021 MicroPort CardioFlow Participates in the 32nd GW-ICC, Drawing Expert Attention on Clinical Application of Motorized Retrievable Valve System. 2021-11-05. Shanghai, China, …See details»
MicroPort CardioFlow Medtech Corporation
MicroPort CardioFlow Medtech Corporation. 2 Disclaimer 2 This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the …See details»
MicroPort® CardioFlow Completes the First Implantation of …
Moscow, Russia, 04 January 2024 — On December 18, 2023, MicroPort ® CardioFlow completed the first implantation of its VitaFlow Liberty ® Transcatheter Aortic Valve and Retrievable …See details»
VitaFlow®’s 7-Year Follow-Up Data Presents at PCR London
London, UK, 14 December 2023 — Recently, evidence-based data from the VitaFlow ® Transcatheter Aortic Valve (VitaFlow ®), developed by MicroPort ® CardioFlow, were revealed …See details»